Animal models for ebolavirus countermeasures discovery: what defines a useful model?
- PMID: 26004783
- DOI: 10.1517/17460441.2015.1035252
Animal models for ebolavirus countermeasures discovery: what defines a useful model?
Abstract
Introduction: Ebolaviruses are highly pathogenic filoviruses, which cause disease in humans and nonhuman primates (NHP) in Africa. The Zaire ebolavirus outbreak in 2014, which continues to greatly affect Western Africa and other countries to which the hemorrhagic fever was exported due to travel of unsymptomatic yet infected individuals, was complicated by the lack of available licensed vaccines or therapeutics to combat infection. After almost a year of research at an increased pace to find and test vaccines and therapeutics, there is now a deeper understanding of the available disease models for ebolavirus infection. Demonstration of vaccine or therapeutic efficacy in NHP models of ebolavirus infection is crucial to the development and eventual licensure of ebolavirus medical countermeasures, so that safe and effective countermeasures can be accelerated into human clinical trials.
Areas covered: The authors describe ebolavirus hemorrhagic fever (EHF) disease in various animal species: mice, guinea pigs, hamsters, pigs and NHP, to include baboons, marmosets, rhesus and cynomolgus macaques, as well as African green monkeys. Because the NHP models are supremely useful for therapeutics and vaccine testing, emphasis is placed on comparison of these models, and their use as gold-standard models of EHF.
Expert opinion: Animal models of EHF varying from rodents to NHP species are currently under evaluation for their reproducibility and utility for modeling infection in humans. Complete development and licensure of therapeutic agents and vaccines will require demonstration that mechanisms conferring protection in NHP models of infection are predictive of protective responses in humans, for a given countermeasure.
Keywords: African green; FDA animal efficacy rule; animal model; antiviral; countermeasure; cynomolgus; ebolavirus; filoviruses; guinea pig; hamster; hemorrhagic fever; in vivo; macaque; marmoset; mice; nonhuman primate; pig; rhesus; therapeutics; vaccine.
Similar articles
-
Nonhuman primates as models for the discovery and development of ebolavirus therapeutics.Expert Opin Drug Discov. 2011 Mar;6(3):233-50. doi: 10.1517/17460441.2011.554815. Expert Opin Drug Discov. 2011. PMID: 22647202
-
Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models.Methods Mol Biol. 2017;1628:293-307. doi: 10.1007/978-1-4939-7116-9_24. Methods Mol Biol. 2017. PMID: 28573630
-
Evaluation of Ebola Virus Countermeasures in Guinea Pigs.Methods Mol Biol. 2017;1628:283-291. doi: 10.1007/978-1-4939-7116-9_23. Methods Mol Biol. 2017. PMID: 28573629 Free PMC article.
-
Ebola Virus: Pathogenesis and Countermeasure Development.Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi: 10.1146/annurev-virology-092818-015708. Annu Rev Virol. 2019. PMID: 31567063 Review.
-
Ebola virus vaccines - reality or fiction?Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. doi: 10.1080/14760584.2016.1178068. Epub 2016 May 9. Expert Rev Vaccines. 2016. PMID: 27078187 Free PMC article. Review.
Cited by
-
Tip Your Cap for Ebola Virus Neutralization.Immunity. 2018 Aug 21;49(2):204-206. doi: 10.1016/j.immuni.2018.08.001. Immunity. 2018. PMID: 30134198 Free PMC article.
-
Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters.J Infect Dis. 2018 Nov 22;218(suppl_5):S438-S447. doi: 10.1093/infdis/jiy457. J Infect Dis. 2018. PMID: 30192975 Free PMC article.
-
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z. Nat Commun. 2018. PMID: 30275474 Free PMC article.
-
Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model.Sci Rep. 2018 Jan 19;8(1):1250. doi: 10.1038/s41598-018-19638-x. Sci Rep. 2018. PMID: 29352230 Free PMC article.
-
Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.Expert Rev Vaccines. 2020 Jan;19(1):85-103. doi: 10.1080/14760584.2020.1713756. Epub 2020 Jan 30. Expert Rev Vaccines. 2020. PMID: 31937163 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical